Cat. No. | Product name | CAS No. |
DC66977 | Aveo anti-RON Featured | |
DC66978 | Anti-MSPR/RON/CD136 Antibody (H5B14) Featured | |
DC66979 |
Ensituximab
Featured
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer. |
1092658-06-4 |
DC66980 |
Gatipotuzumab
Featured
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC). |
1264737-26-9 |
DC66981 |
Clivatuzumab
Featured
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. |
1622075-09-5 |
DC66982 | Oregovomab Featured | |
DC66983 |
Abagovomab
Featured
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc). |
792921-10-9 |
DC66984 |
Sofituzumab
Featured
Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody. |
1615692-28-8 |
DC66985 | Forerunner patent anti-Muc 17 Featured | |
DC66986 | Argenx patent anti-MuSK Featured | |
DC66987 | Alt-100 Featured | |
DC66988 |
Lifastuzumab
Featured
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
1615697-16-9 |
DC66989 |
Upifitamab
Featured
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. |
2254118-43-7 |
DC66990 |
Lorvotuzumab
Featured
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. |
339306-30-8 |
DC66991 |
Enfortumab
Featured
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. |
1448664-46-7 |
DC66992 |
Tanezumab
Featured
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. |
880266-57-9 |
DC66993 |
Fasinumab
Featured
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies. |
1190239-42-9 |
DC66994 | MEDI-578 Featured | |
DC66995 |
Fulranumab
Featured
Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain. |
902141-80-4 |
DC66996 | AS2886401-00 Featured | |
DC66997 |
Monalizumab
Featured
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
1228763-95-8 |
DC66998 |
Tesnatilimab
Featured
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD). |
2242758-08-1 |